131 related articles for article (PubMed ID: 30646464)
21. High incidence of intolerance to tuberculosis chemoprophylaxis.
Haroon M; Martin U; Devlin J
Rheumatol Int; 2012 Jan; 32(1):33-7. PubMed ID: 20658233
[TBL] [Abstract][Full Text] [Related]
22. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
Fluegge KR
J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
[TBL] [Abstract][Full Text] [Related]
23. Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island.
Kwara A; Herold JS; Machan JT; Carter EJ
Chest; 2008 Apr; 133(4):862-8. PubMed ID: 18071014
[TBL] [Abstract][Full Text] [Related]
24. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME;
Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821
[TBL] [Abstract][Full Text] [Related]
25. Rhabdomyolysis Induced by Isoniazid in a Patient with Rheumatoid Arthritis and End-stage Renal Disease: A Case Report and Review of the Literature.
Komai T; Sumitomo S; Teruya S; Fujio K
Intern Med; 2018 Aug; 57(16):2413-2416. PubMed ID: 29526956
[TBL] [Abstract][Full Text] [Related]
26. A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework.
Sadatsafavi M; Marra C; Marra F; Moran O; FitzGerald JM; Lynd L
Value Health; 2013; 16(1):66-75. PubMed ID: 23337217
[TBL] [Abstract][Full Text] [Related]
27. Follow-up results of isoniazid chemoprophylaxis during biological therapy in Colombia.
Cataño JC; Morales M
Rheumatol Int; 2015 Sep; 35(9):1549-53. PubMed ID: 25763992
[TBL] [Abstract][Full Text] [Related]
28. Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents.
Bourré-Tessier J; Arino-Torregrosa M; Choquette D
Clin Rheumatol; 2014 Aug; 33(8):1049-53. PubMed ID: 24554383
[TBL] [Abstract][Full Text] [Related]
29. Benefit of treatment of latent tuberculosis infection in individual patients.
Dobler CC; Martin A; Marks GB
Eur Respir J; 2015 Nov; 46(5):1397-406. PubMed ID: 26405292
[TBL] [Abstract][Full Text] [Related]
30. Treatment guidelines for latent tuberculosis infection.
;
Kekkaku; 2014 Jan; 89(1):21-37. PubMed ID: 24654427
[TBL] [Abstract][Full Text] [Related]
31. Detection and management of latent tuberculosis in liver transplant patients.
Jafri SM; Singal AG; Kaul D; Fontana RJ
Liver Transpl; 2011 Mar; 17(3):306-14. PubMed ID: 21384513
[TBL] [Abstract][Full Text] [Related]
32. Use of Rifapentine and Isoniazid Directly Observed Therapy for the Treatment of Latent Tuberculosis Infection in a Military Clinic.
Jinbo J; Lustik M; West GF; Kloetzel M
Mil Med; 2017 Sep; 182(9):e2024-e2029. PubMed ID: 28885972
[TBL] [Abstract][Full Text] [Related]
33. [Adverse effect other than liver dysfunction in treatment of latent tuberculous infection by isoniazid].
Ito K; Hoshino H; Nakazono T; Masuyama H; Sugita H; Yoshiyama T; Kato S
Kekkaku; 2007 Jan; 82(1):1-9. PubMed ID: 17310776
[TBL] [Abstract][Full Text] [Related]
34. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
Tsai TF; Ho V; Song M; Szapary P; Kato T; Wasfi Y; Li S; Shen YK; Leonardi C;
Br J Dermatol; 2012 Nov; 167(5):1145-52. PubMed ID: 22803615
[TBL] [Abstract][Full Text] [Related]
35. Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting.
Conti A; Piaserico S; Gisondi P; Odorici G; Galdo G; Lasagni C; Pellacani G
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28547750
[TBL] [Abstract][Full Text] [Related]
36. Fluoroquinolones for the treatment of latent
Silva JT; San-Juan R; Fernández-Ruiz M; Aguado JM
World J Gastroenterol; 2019 Jul; 25(26):3291-3298. PubMed ID: 31341356
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
Medina-Gil C; Dehesa L; Vega A; Kerdel F
Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
[TBL] [Abstract][Full Text] [Related]
38. [[LIVER TOXICITY DUE TO RIFAMPICIN MONOTHERAPY IN LATENT TUBERCULOSIS INFECTION].].
Ito K
Kekkaku; 2016 May; 91(5):509-513. PubMed ID: 28661592
[TBL] [Abstract][Full Text] [Related]
39. Latent tuberculosis infection: Opportunities and challenges.
Chee CBE; Reves R; Zhang Y; Belknap R
Respirology; 2018 Oct; 23(10):893-900. PubMed ID: 29901251
[TBL] [Abstract][Full Text] [Related]
40. [Development of eosinophilic pneumonia in a patient with latent tuberculosis infection resulting from isoniazid].
Umeda N; Inada Y; Mamoto T
Kekkaku; 2014 Oct; 89(10):777-80. PubMed ID: 25730952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
